Kornimate/medical-research-clean huggingface dataset:
the influence of conversation map on the health behaviors of diabetes patients

Conditions: Diabetes Mellitus; Health Knowledge, Attitudes, Practice; Health Behavior; Glycated Hemoglobin (HbA1c)

Summary: the american diabetes association indicates that diabetes self-management is a skill that diabetic patients must learn in the diabetes self-management education; thus, this contributes to shared care for diabetes, in which teams of physicians, professional nurses, and dietitians offer shared care to patients. however, according to the statistical analysis of the conditions of glycemic control in diabetic patients in 28 countries across 4 continents (asia, africa, europe, and south america), the mean glycated hemoglobin (hba1c) of the 12,727 patients was 9.5% by litwak et al. in 2013. in taiwan, a national survey among diabetic patients in a shared-care program found that the percentage of patients with hba1c lower than 7% increased by 6.5% from 2006 to 2011; yet, among the 720 patients who completed both surveys in 2006 and 2011, the percentage with hba1c lower than 7% decreased by 2.1% during that period. these results suggest that despite the increase in the proportion of patients who successfully managed their diabetes, some patients still encountered difficulty in glycemic control.therefore, numerous health education tools on diabetes continue to be developed. in 2011,joann et al. determined that the mode of health care had a substantial influence on the dietary habits of diabetic patients, and that individual health education had the largest effect on diabetes control. in addition, using the conversation map for diabetes control also had a substantial influence on improving health behaviors. among existing studies that have adopted the conversation map, no large-scale research has been conducted, the research samples and relevant studies in taiwan have been scant, and no theoretical foundation has been applied in evaluating the effects of the conversation map. accordingly, the investigators aimed to enhance the mutual experience exchange and learning among diabetic patients through adopting the conversation map to observe its influence on their health behaviors by incorporating it into existing health education modalities. furthermore, on the basis of the health belief model, a relevant questionnaire was designed for assessing the effectiveness of glycemic control in diabetic patients.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus between 30 and 80 years of age who participated in a diabetes shared-care program. exclusion criteria: * patients were excluded if they had renal insufficiency (egfr \<30 ml•min / 1.732), were not ambulatory, or were unable to answer the questionnaire independently.
cardiac disease and the electrocardiogram in sci patients

Conditions: Spinal Cord Injury

Summary: the purpose of this three-year study is to determine the prevalence and incidence of the different types of cardiac disease and ecg abnormalities in sci patients. study goals are: (i) delineation of the specific types of heart disease that occur in the sci population as manifested both pre-clinically and clinically and (ii) demonstration of their association with ecg findings. this will enable validation of scores and algorithms using the inexpensive and widely available ecg for the prevention of heart disease as well as it's early treatment and rehabilitation in sci patients. the findings will be helpful in demonstrating what cardiological tests are appropriate for the mandated annual evaluation of sci patients.

the purpose of this three-year study is to determine the prevalence and incidence of the different types of cardiac disease and ecg abnormalities in sci patients seen at the pava scic and their association. study goals include: i) delineation of the specific types of heart disease that occur in the sci population as manifested both pre-clinically and clinically and ii) demonstration of their association with ecg findings. this will enable validation of scores and algorithms using the inexpensive and widely available ecg for the prevention of heart disease as well as it's early treatment and rehabilitation in sci patients. our findings will be helpful in demonstrating what cardiological tests are appropriate for the mandated annual evaluation of sci patients. there are two components to this study: an outcomes component to complete information previously gathered in clinical and computerized databases of 800 sci patients and a convenience sample of age-matched able-bodied veterans and perform a follow up for cardiac events. a screening component to identify pre-clinical disease will include holter ecg recordings and echocardiograms on patients without symptoms or evidence for heart disease seen in the sci center during the course of the study and age-matched able-bodied veterans. hypothesis (a): the prevalence and incidence of cardiac diseases including coronary artery disease and cardiomyopathy will be higher in the sci population than age-matched samples of the able-bodied population while valvular disease and arrhythmia will be similar. (b): the prevalence and incidence of cardiac disease in sci individuals will be associated with level and completeness of injury (ie, higher occurrence in those with higher lesion levels and more complete injuries.) (c) the ecg will be helpful in sci patients in early identification and secondary prevention of both ischemic and cardiomyopathic heart disease. (d) continuous holter ecg recordings or echocardiograms will only be indicated for screening specific sci patients identified by clinical and electrocardiographic features.

Eligibility criteria:
sci patients

Keywords: spinal cord injury, heart disease, electrocardiography
the sarcoma biology and outcome project

Conditions: Sarcoma; Malignant Mesenchymoma; Sarcoma of Bone and Connective Tissue

Summary: sarcbop - an interdisciplinary and translational registry sarcbop aims to establish a database that integrates every aspect possibly relevant to sarcoma treatment and research. sarcbop thus will not be limited to specific questions or patient groups, but instead will build a comprehensive database including clinical, pathologic, and radiologic information, multi-layered molecular data, and patient-reported outcomes, combined with a dedicated biobank for tissue samples and liquid biopsies. as the study integrates seamlessly with the clinical activities of the heidelberg sarcoma center, the molecular diagnostics program of nct heidelberg, including the nct/dktk master program, and with the nct trial center, including the pmo clinical trials program, sarcbop will generate a comprehensive and continuously growing resource for clinicians, researchers, and, finally, patients.

the following data are collected and stored: * demographics * comorbidities * clinical characteristics at diagnosis, relapse and progression * radiologic images * histological images * treatments including drg and ops data, including detailed information on surgical, radiation, and medical therapy as well as treatment relevant follow-up data * longitudinal disease assessments * clinical outcome * genomic, transcriptomic, epigenomic and proteomic data * patient reported outcomes furthermore, biological samples are collected and processed by the sample processing laboratory of the heidelberg center for personalized oncology and the nct biobank.

Eligibility criteria:
inclusion criteria: * suspected or proven diagnosis of soft-tissue or bone sarcoma (stbs) * age ≥12 years * ability to understand nature and individual consequences of the registry * written informed consent * subjects who are physically or mentally capable of giving consent exclusion criteria: • severe neurological or psychiatric disorder interfering with the ability to give written informed consent

Keywords: rare disease database treatment research molecular diagnostic translational approach interdisciplinary approach
safety of iodinated contrast in liver transplant candidates with decreased renal function undergoing coronary ct angiography

Conditions: Acute Kidney Injury; Renal Insufficiency, Chronic; Contrast-induced Nephropathy; Liver Transplantation; Contrast Media

Summary: this study evaluates the safety of iodinated contrast medium administered to liver transplant candidates with decreased renal function undergoing coronary ct angiography. incidence of post-contrast acute kidney injury in liver transplant candidates with decreased renal function and normal renal function will be compared.

low osmolar non-ionic contrast medium (locm) is routinely used for contrast-enhanced computed tomography (ct) including coronary computed tomography angiography (ccta). this study evaluates the effect of locm on liver transplant candidates with normal and decreased renal function undergoing ccta. incidence of post-contrast acute kidney injury (pc-aki) will be compared between the two groups before and after contrast medium exposure. locm is a potential cause of pc-aki, especially in vulnerable population with decreased renal function. according to the american college of radiology (acr) manual on contrast media, however, many published studies on pc-aki in the past have been heavily contaminated by bias and conflation. more recent studies do not confirm a high risk of contrast induced nephropathy. end stage liver disease patients with normal renal function do not seem to be at a higher risk of developing pc-aki. only limited data reporting a low incidence of pc-aki after contrast-enhanced ct in patients with liver cirrhosis and concomitant decreased renal function exists. proof of low pc-aki in this specific population would allow to redirect patients from invasive catheterization to ccta as their cardiac clearance before transplantation. this study will prospectively investigate the incidence of pc-aki in this specific at-risk population.

Eligibility criteria:
inclusion criteria: - liver transplant candidate, age \> 21 referred for coronary ct angiography, medium-risk patient for coronary artery disease exclusion criteria: * liver transplant candidates who are at low-risk for coronary artery disease and therefore do not need coronary ct angiography or invasive catheterization * liver transplant candidates who are at high-risk for coronary artery disease and are referred directly to invasive catheterization * candidates with chronic kidney disease stage 4, with egfr \<30 ml/min/1.73m2 * known or suspected allergy to standard iodine contrast medium

Keywords: contrast-induced nephropathy contrast-induced acute kidney injury coronary computed tomography angiography
the doses of systemic steroid in acute exacerbation of chronic obstructive pulmonary disease (aecopd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: it is well established that steroid use is a benefit in the treatment of chronic obstructive pulmonary disease (copd) with acute exacerbation (ae). but it is still debated about the regimen and dosage of steroid use. from this retrospective review of medical charts, the researchers investigated the therapeutic impact of various steroid dosages in copd with ae.

data collection from medical charts was conducted at far eastern memorial hospital, a tertiary-care hospital with around 900 beds. patients who were admitted from january 2008 to december 2008 and diagnosed as having chronic obstructive pulmonary disease with acute exacerbation (code icd-9: 491.21) were included in this study. the study was approved by the institutional review board of the far eastern memorial hospital (femh:098097-3). demographic data, medical histories and medicine prescriptions at outpatient clinics, emergency and inpatient departments were collected. the initial presentations of acute exacerbation and laboratory data were also summarized from the records of the emergency department. the reports of pulmonary function tests within 6 months before or after the exacerbations were included while reviewing the charts. the probability of concomitant pneumonia (paecopd) was determined by attending physicians and reviewed by the investigator according to the radiologic findings. if there were incoherent opinions about the probability of pneumonia between the physicians and the investigator, it was determined by another independent pulmonologist. the highest daily doses and total doses of systemic steroids were calculated and recorded as the equivalent doses of prednisolone (1 mg methylprednisolone is equal to 1.25 mg prednisolone; 1 mg hydrocortisone is equal to 0.25 mg prednisolone). the subjects were divided into 3 groups according to the highest daily dose of steroids as follows: patients receiving more than 60 mg/day were designated to the hd group; those receiving less than or equal to 60 mg/day to the ld group; and those who did not receive any steroids during admission to the nil group. the length of stay (los) was defined as the duration from admission to the emergency department to discharge. hyperglycemia, psychosis, nosocomial infections and active peptic ulcer diseases were regarded as acute side effects of systemic steroids. hyperglycemia was defined as a new blood sugar level of more than 200 mg/dl in patients without a history of diabetic mellitus, or an increment in diabetes medications. the relapse rate within 30 days was assessed by outpatient follow-up records.

Eligibility criteria:
inclusion criteria: * from january 2008 to december 2008, patients were admitted and diagnosed as having chronic obstructive pulmonary disease with acute exacerbation (code icd-9: 491.21) exclusion criteria: -

Keywords: chronic obstructive pulmonary disease systemic steroid
surgical treatment to greater anterior vaginal prolapse

Conditions: Hernia; Cystocele

Summary: a rct study to compare traditional colporrhaphy versus polypropylene mesh in treatment of the anterior vaginal wall prolapse.

seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair( nazca tc™ pop repair system) . the primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, length of hospitalization, and adverse events.

Eligibility criteria:
inclusion criteria: * women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not,point (ba)ics96, below hymenal ring requiring surgical correction were eligible for participation. exclusion criteria: patients were excluded if they had: * stage 0 or i (ics96) anterior vaginal support * declined participation * were pregnant or contemplating future pregnancy * had prior anterior vaginal prolapse repair with biologic or synthetic graft * active or latent systemic infection * compromised immune system * uncontrolled diabetes mellitus, * previous pelvic irradiation or cancer * known hypersensitivity to polypropylene.

Keywords: anterior vaginal prolapse traditional treatment mesh, graft nazca tc™ pop repair system colporrhaphy
efficacy and safety of mitoxantrone in patients with refractory neuromyelitis optica and spectrum disorders

Conditions: Neuromyelitis Optica; Neuromyelitis Optica Spectrum Disorders

Summary: the treatment protocol consisted of 12 mg/m2 mito intravenous infusions every 3 months for 2 years. dosage was adjusted according to side effects. neurological assessment including the determination of the expanded disability status scale (edss) score and ophthalmologic evaluations were performed every 3 months and during relapses. flow cytometric analysis, brain and spinal cord mri was performed at baseline, 6, 12, 18, and 24 months.


Eligibility criteria:
inclusion criteria: * recurrent longitudinal myelitis (\>3 segments of spinal cord involvement by mri) with or without recurrent on (unilateral or bilateral) but with normal brain mri and positive serological nmo igg antibody. * recurrent longitudinal myelitis (\>3 segments of spinal cord involvement by mri) with or without spatially limited brain lesion and positive serological nmo igg antibody. * nmo, fulfilled wingerchuk 2006 criteria for nmo. * patient presented at least 2 relapses during the 12 months preceding the start of mitoxantrone therapy, despite immunotherapies using corticosteroid, interferon beta, azathioprine, cyclophosphamide, cyclosporin a, mycophenolate mofetil or a combination of these drugs * extended disability status score 3-8. * normal range for white-blood-cell count (more than 4×109/l), neutrophil count (more than 2×109/l), and platelet count (more than 100×109/l). exclusion criteria: * cardiac risk factors (e.g history of congestive heart failure and left ventricular ejection fraction (lvef) \< 50% * systemic diseases such as lupus, sjogren's syndrome, anti-phospholipid antibody syndrome, sarcoidosis, rheumatoid arthritis, or vitamin b12 deficiency * previous treatment with mitoxantrone or anthracyclines * pregnant or planning to be pregnant * patients with severe liver disorders (who grade 4)

Keywords: mitoxantrone neuromyelitis optica relapse
effects of omega-3 fatty acids on risk factors for breast cancer in pre-menopausal women

Conditions: Healthy; Premenopausal Period

Summary: healthy premenopausal women were enrolled in a diet intervention study that examined the effect of a combination epa/dha supplement on risk factors associated with breast cancer. in a randomized cross-over design, women consumed their habitual diet with a supplement for three menstrual cycles, had three cycles of wash-out and then consumed a low-fat diet with the same supplement. blood, urine and nipple aspirate fluid were collected periodically over the 10 month protocol and analyzed for biomarkers associated with supplementation and future risk of breast cancer.

non-pregnant, non-lactating women aged 18+ were recruited by way of posters, to take part in a dietary intervention study that was examining the effects of dietary fat level and fat type on risk factors associated with breast cancer. women who were normally menstruating, consumed either their habitual diet or a low-fat diet for three menstrual cycles, along with a supplement containing 1.2 g dha+epa /day. this was followed by a 3-menstrual cycle washout, where the habitual diet was consumed without a supplement. subsequently the participants consumed the other diet (either low-fat or habitual) for a further 3 menstrual cycles with the 1.2 g dha/epa supplement. blood, urine and nipple aspirate fluid were collected at the beginning and end of each intervention period and analyzed for a variety of biomarkers. diet records were collected continuously over the entire study period and periodic 7-day records examined for collection of detailed nutrition information. anthropometry was completed at each study visit, and nutritional counselling provided throughout.

Eligibility criteria:
inclusion criteria: menstruating, pre-menopausal - exclusion criteria: pregnant, lactating, post-menopausal, smoking, on birth control pills -

Keywords: breast cancer fatty acids omega-3
lamivudine plus interferon versus lamivudine for the treatment of hbeag positive chronic hepatitis b virus (hbv)

Conditions: Chronic Hepatitis B

Summary: this is a single-centre prospective randomised study comparing the virological and histological response of hbv infection to lamivudine in combination with interferon versus lamivudine alone.


Eligibility criteria:
inclusion criteria: * untreated chronic hepatitis b patients with evidence of hbv replication as documented by serum hnv-dna positive within 3 months prior to entry and serum hbeag positive at screening. * documented presence of abnormal alanine aminotransferase (alt) (1.3 - 5x upper limit normal (uln)) within 1 month prior to entry and signs of compensated liver disease. exclusion criteria: * patients with any cause for liver disease other than chronic hepatitis b and evidence or history of decompensated liver disease.

Keywords: hbeag-positive chronic hepatitis b lamivudine seroconversion chronic hepatitis b
ndph biomarker study in children and adolescents

Conditions: New Persistent Daily Headache

Summary: this study will recruit pediatric patients with ndph (new daily persistent headache), characterize their headache in a standard manner, and treat the ndph with standard medications used for treatment of headaches in this population. response to treatment with cgrp blocking ab medications will be evaluated. biomarkers related to headache disorders will be measured before and after treatment.

subjects age 10-18 with diagnosis of ndph (international classification of headache disorders d ichd-3 criteria) will be recruited for the study. consenting subjects will receive standard headache care and treatment, including treatment with cgrp blocking ab medications. blood will be drawn before and after treatment, with assessment of calcitonin gene related peptid, pituitary adenylate cyclase activating peptid (pacap), brain derived neurotrophic factor (bdnf), nerve growth factor (ngf), and tumor necrosis factor alpha, and vasointestinal peptic (vip) before and after treatment.

Eligibility criteria:
inclusion criteria: * patients between 10-18 yo with diagnosis of new daily persistent headache (ichd-3 criteria) who have normal developmental history for age * subject and parent legal guardian able to communicate in english, understand and consent to study * subject will to undergo monthly injections at home for treatment of ndph * normal neuro imaging * no prior treatment with cgrp blocking medications or botulinum toxin exclusion criteria: * history of reynauds syndrome * history of concussion or prior neurosurgery * any structural brain lesion including hydrocephalus, congenital anomalies (including chiari malformation) * history of psychiatric disorders * history of any headache disorder (including migraine) prior to the diagnosis of ndph * pregnancy * prior treatment with any cgrp blocking medication * treatment with botulinum toxin injections previously * any other condition that in the opinion of the pi would interfere with the planned study treatment

Keywords: npdh cgrp pacap bdnf ngf tnf-alpha vip biomarker